Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 24, Issue 12, 2012, Pages 1504-1513

  Moore, David J ^a   Blackstone, Kaitlin ^b   Woods, Steven Paul ^a   Ellis, Ronald J ^c   Atkinson, J Hampton ^a   Heaton, Robert K ^a   Grant, Igor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiretroviral; cognition; HIV AIDS; medication adherence; methamphetamine

Indexed keywords

METHAMPHETAMINE; VIRUS RNA;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; ATTENTION DEFICIT DISORDER; CEREBROSPINAL FLUID LEVEL; COGNITION; COMORBIDITY; EDUCATIONAL STATUS; ETHNICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; METHAMPHETAMINE DEPENDENCE; MIXED INFECTION; NEUROPSYCHIATRY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPATHY; SELF REPORT; TREATMENT OUTCOME; TREATMENT REFUSAL; VIRUS LOAD;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; METHAMPHETAMINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84868588889     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121.2012.672718     Document Type: Article

References (58)

1. Andrade, A.S., McGruder, H.F., Wu, A.W., Celano, S.A., Skolasky, R.L. Jr., Selnes, Q.A., McArthur, J.C. 2005. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clinical Infectious Disease 41 (6), 875-882.
2. Atkinson, J.H., and, Grant, I. 1994. Natural history of neuropsychiatric manifestations of HIV disease. Psychiatric Clinics of North America, 17 (1): 17-33.
3. Arnsten, J.H., Demas, P.A., Farzadegan, H., Grant, R.W., Gourevitch, M.N., Chang, C.J., and, Schoenbaum, E.E. 2001. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Disease, 33 (8): 1417-1423.
4. Bangsberg, D.R., Hecht, F.M., Charlebois, E.D., Zolopa, A.R., Holodniy, M., Sheiner, L., and, Moss, A. 2000. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14: 357-366.
5. Blashill, A.J., Perry, N., and, Safren, S.A. 2011. Mental health: A focus on stress, coping, and mental illness as it relates to treatment retention, adherence, and other health outcomes. Current HIV/AIDS Reports, 8 (4): 215-222.
6. Bose, S., Varanasi, A., and, Mo, G. 2009. Demographic, socio-economic and psychological determinants of HIV treatment: A community out-patient experience. British Journal of Medical Practitioners, 2 (2): 42-45.
7. Bottonari, K.A., Safren, S.A., McQuaid, J.R., Hsiao, C., and, Roberts, J.E. 2010. A longitudinal inventigation of the impact of life stress on HIV treatment adherence. Journal of Behavioral Medicine, 33: 486-495.
8. Bouhnik, A.D., Chesney, M., Carrieri, P., Gallais, H., Moreau, J., Moatti, J.P., and, Spire, B. 2002. Nonadherence among HIV-infected injecting drug users: the impact of social instability. Journal of Acquired Immune Deficiency Syndromes, 31 (Suppl 3): S149-S153.
9. Brook, D.W., Brook, J.S., Zhang, C., Cohen, P., and, Whiteman, M. 2002. Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Archives of General Psychiatry, 59 (11): 1039-1044.
10. Brooner, R.K., Bigelow, G.E., Strain, E., and, Schmidt, C.W. 1990. Intravenous drug abusers with antisocial personality disorder: Increased HIV risk. Drug and Alcohol Dependence, 26 (1): 39-44.
11. Brooner, R.K., Greenfield, L., Schmidt, C.W., and, Bigelow, G.E. 1993. Antisocial personality disorder and HIV infection among intravenous drug abusers. American Journal of Psychiatry, 150: 53-58.
12. Burton, C.L., Strauss, E., Hultsch, D.F., and, Hunter, M.A. 2006. Cognitive functioning and everyday problem solving in older adults. Clinical Neuropsychologist, 20 (3): 432-452.
13. Carey, C.L., Woods, S.P., Gonzalez, R., Conover, E., Marcotte, T.D., Grant, I., and, Heaton, R.K. 2004. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. Journal of Clinical and Experimental Neuropsychology, 26 (3): 307-319.
14. Carrico, A.W. 2011. Substance use and HIV disease progression in the HAART era: Implications for the primary prevention of HIV. Life Sciences, 88 (21-22): 940-947.
15. Chan, Y.F., Dennis, M.L., and, Funk, R.R. 2006. Prevalence and comorbidiity of major internalizing and externalizing problems among adolescents and adults presenting to substance abuse treatment. Journal of Substance Abuse Treatment, 34 (1): 14-24.
16. Chander, G., Himelhoch, S., and, Moore, R.D. 2006. Substance abuse and psychiatric disorders in HIV-positive patients: Epidemiology and impact on antiretroviral therapy. Drugs, 66 (6): 769-789.
17. Chang, L.W., Kagaayi, J., Nakigozi, G., Packer, A.H., Serwadda, D., Quinn, T.C., and, Reynolds, S.J. 2008. Responding to the human resource crisis: Peer health workers, mobile phones, and HIV care in Rakai, Uganda. AIDS Patient Care & STDS, 22 (3): 173-174.
18. Cherner, M., Suarez, P., Lazzaretto, D., Fortuny, L.A., Mindt, M.R., Dawes, S., and, Heaton, R.K. 2007. Demographically corrected norms for the Brief Visuospatial Memory Test-revised and Hopkins Verbal Learning Test-revised in monolingual Spanish speakers from the U.S.-Mexico border region. Archives in Clinical Neuropsychology, 22 (3): 343-353.
19. Chesney, M.A., Ickovics, J.R., Chambers, D.B., Gifford, A.L., Neidig, J., Zwicki, B., and Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). 2000. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12 (3): 255-266.
20. Coady, M.H., Latka, M.H., Thiede, H., Golub, E.T., Ouellet, L., Hudson, S.M., and, Garfein, R.S. 2007. Housing status and associated differences in HIV risk behaviors among young injection drug users (IDUs). AIDS & Behavior, 11 (6): 854-863.
21. Des Jarlais, D.C. 1999. Psychoactive drug use and progression of HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 20 (3): 272-274.
22. Ellis, R.J., Childers, M.E., Cherner, M., Lazzaretto, D., Letendre, S., and, Grant, I. 2003. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. Journal of Infectious Diseases, 188 (12): 1820-1826.
23. Ettenhoffer, M.L., Foley, J., Castellon, S.A., and, Hinkin, I. 2010. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology, 74 (15): 1217-22.
24. Gifford, A.L., Bormann, J.E., Shively, M.J., Wright, B.C., Richman, D.D., and, Bozzette, S.A. 2000. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 23 (5): 386-395.
25. Healthy Living Project Team. 2007. Effects of a behavioral intervention to reduc risk of transmission among people living with HIV: The Healthy Living Project randomized controlled study. Journal of Acquired Deficiency Syndrome, 44, 213-221.
26. Heaton, R.K., Marcotte, T.D., Mindt, M.R., Sadek, J., Moore, D.J., Bentley, H., and The HNRC Group. 2004. The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal for the International Neuropsychological Society, 10 (3): 317-331.
27. Heaton, R.K., Clifford, D.B., Franklin, D.R. Jr., Woods, S.P., Ake, C., Vaida, F., Grant, I., for the CHARTER Group. 2010. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75 (23), 2087-2096.
28. Hinkin, C.H., Castellon, S.A., Durvasula, R.S., Hardy, D.J., Lam, M.N., Mason, K.I., and, Stefaniak, M. 2002. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology, 59 (12): 1944-1950.
29. Hinkin, C.H., Hardy, D.J., Mason, K.I., Castellon, S.A., Durvasula, R.S., Lam, M.N., and, Stefaniak, M. 2004. Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS, 18 (Suppl 1): S19-S25.
30. Hinkin, C.H., Barclay, T.R., Castellon, S.A., Levine, A.J., Durvasula, R.A., Marion, S.D., and, Longshore, D. 2007. Drug use and medication adherence among HIV-1 infected individuals. AIDS & Behavior, 11 (2): 185-194.
31. Hirsch, M.S., Gunthard, H.F., Schapiro, J.M., Brun-Vézinet, F., Clotet, B., Hammer, S.M., and, Richman, D.D. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. Journal of the American Medical Association, 283 (18): 2417-2426.
32. Leventhal, A.M., Kahler, C.W., Ray, L.A., Stone, K., Young, D., Chelminski, I., and, Zimmerman, M. 2008. Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder. The American Journal on Addictions, 17 (3): 218-223.
33. Levine, A.J., Hinkin, C.H., Marion, S., Keuning, A., Castellon, S.A., Lam, M.M., and, Durvasula, R.S. 2006. Adherence to antiretroviral medications in HIV: Differences in data collected via self-report and electronic monitoring. Health Psychology, 25 (3): 329-335.
34. Lu, M., Safren, S.A., Skolnik, P.R., Rogers, W.H., Coady, W., Hardy, H., and, Wilson, I.B. 2008. Optimal recall period and response task for self-reported HIV medication adherence. AIDS & Behavior, 12 (1): 86-94.
35. Malta, M., Strathdee, S.A., Magnanini, M.M., and, Bastos, F.I. 2008. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review. Addiction, 103 (8): 1242-1257.
36. Marquez, C., Mitchell, S.J., Hare, C.B., John, M., and, Klausner, J.D. 2009. Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004-2006. AIDS Care, 21 (5): 575-582.
37. Mellins, C.A., Brackis-Cott, E., Leu, C., Elkington, K.S., Dolezal, C., Wiznia, A., and, Abrams, E.J. 2009. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. Journal of Child Psychology and Psychiatry, 50 (9): 1131-1138.
38. Norman, M.A., Moore, D.J., Taylor, M.J., Franklin, D., Cysique, L., Ake, C., and The HNRC Group. 2011. Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. Journal of Clinical and Experimental Neuropsychology, 33: 793-804.
39. Palepu, A., Tyndall, M., Yip, B., O'Shaughnessy, M.V., Hogg, R.S., and, Montaner, J.S. 2003. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes, 32 (5): 522-526.
40. Puccio, J.A., Belzer, M., Olson, J., Martinez, M., Salata, C., Tucker, D., and, Tanaka, D. 2006. The use of cell phone reminder calls for assisting HIV-infected adolescents and young adults to adhere to highly active antiretroviral therapy: A pilot study. AIDS Patient Care & STDs, 20 (6): 438-444.
41. Reback, C.J., Larkins, S., and, Shoptaw, S. 2007. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care, 15 (6): 775-785.
42. Rippeth, J.D., Heaton, R.K., Carey, C.L., Marcotte, T.D., Moore, D.J., Gonzalez, R., and The HNRC Group. 2004. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. Journal of the International Neuropsychological Society, 10 (1): 1-14.
43. Robins, L.N., Cottler, L., Bucholz, K., &, Compton, W. The Diagnostic Interview Schedule, version IV. St. Louis, MO: Washington University, 1995.
44. Safren, S.A., Hendriksen, E.S., Smeaton, L., Celentano, D.D., Hosseinipour, M.C., Barnett, R., and, Campbell, T. 2012. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS and Behavior, 16: 266-277.
45. Safren, S.A., Duran, P., Yovel, I., Periman, C.A., and, Sprich, S. 2007. Medication adherence in psychopharmacologically treated adults with ADHD. Journal of Attention Disorders, 10 (3): 257-260.
46. Safren, S.A., Hendriksen, E.S., Desousa, N., Boswell, S.L., and, Mayer, K.H. 2003. Use of an online pager sstem to increase adherene to antiretroviral medications. AIDS Care, 15 (6): 787-793.
47. Scott, J.C., Woods, S.P., Matt, G.E., Meyer, R.A., Heaton, R.K., Atkinson, J.H., and, Grant, I. 2007. Neurocognitive effects of methamphetamine: A critical review and meta-analysis. Neuropsychology Review, 17 (3): 275-297.
48. Su, C.Y., Chen, C.C., Wuang, Y.P., Lin, Y.H., and, Wu, Y.Y. 2008. Neuropsychological predictors of everyday functioning in adults with intellectual disabilities. Journal of Intellectual Disability Research, 52: 18-28.
49. Thames, A.D., Kim, M.S., Becker, B.W., Foley, J.M., Hines, L.J., Singer, E.J., Hinkin, C.H. 2010. Medication and finance management among HIV-infected adults: The impact of age and cognition. Journal of Clinlical and Experimental Neuropsychology 1-10.
50. Tucker, J.S., Burnam, M.A., Sherbourne, C.D., Kung, F., and, Gifford, A.L. 2003. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. American Journal of Medince, 114 (7): 573-580.
51. Vigil, O., Posada, C., Woods, S.P., Atkinson, H., Heaton, R.K., Perry, W., and The HNRC Group. 2008. Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. Journal of Clinical and Experimental Neuropsychology, 30 (7): 805-815.
52. Waldrop-Valverde, D. 2005. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting drug users. AIDS Patient Care and STDS, 19 (5): 326-334.
53. Wittchen, H. 1994. Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): A critical review. Journal of Psychiatric Research, 28 (1): 57-84.
54. Wood, E., Montaner, J.S., Yip, B., Tyndall, M.W., Schechter, M.T., O'Shaughnessy, M.V., and, Hogg, R.S. 2003. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ, 169 (7): 656-661.
55. Woods, S.P., Moore, D.J., Weber, E., and, Grant, I. 2009a. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychology Review, 19 (2): 152-168.
56. Woods S.P., Dawson M.S., Weber E., Gibson S., Grant I., &, Atkinson J.H., the HNRC Group. 2009b. Timing is everything: Antiretroviral nonadherence is associated with impairment in time-based prospective memory. Journal of the International Neuropsychological Society 15 (1), 42-52.
57. Woods, S.P., Scott, J.C., Fields, J.A., Poquette, A., and, Troster, A.I. 2008. Executive dysfunction and neuropsychiatric symptoms predict lower health status in essential tremor. Cognitive and Behavioral Neurology, 21 (1): 28-33.
58. World Health Organization. 1990. Composite international diagnostic interview. Geneva, Switzerland.